Company News: Page (1) of 1 - 03/08/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update

- Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1/2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patie... (March 08, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Post/Production,Management,Presentors,Management,Business Issues,Internet Media,Presentation,Corporate/Company,Events, webcast,Disease,Surgery,Science,Lifestyle,Medical,Genetics,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved